Lauritsen K, Rune S J, Wulff H R, Olsen J H, Laursen L S, Havelund T, Astrup L, Bendtsen F, Linde J, Bytzer P
Department of Medical Gastroenterology, Odense University Hospital, Denmark.
Gut. 1988 Feb;29(2):249-53. doi: 10.1136/gut.29.2.249.
We conducted a six week double blind randomised study of 176 patients with prepyloric gastric ulcer to determine whether the proton pump inhibitor, omeprazole 30 mg daily would accelerate healing and pain relief, as compared with cimetidine 1 g daily. At two, four, and six weeks after entry ulcers healed in a larger percentage of patients treated with omeprazole (54, 81, and 86%) than of those treated with cimetidine (39, 73, and 78%) ('intention to treat' cohort; p less than 0.05 at two weeks). A higher proportion of patients on omeprazole became free of pain during the first week of treatment (p less than 0.05). No major clinical or biochemical side effects were noted. Omeprazole is an efficient treatment for patients with prepyloric gastric ulcers.
我们对176例幽门管胃溃疡患者进行了一项为期六周的双盲随机研究，以确定每日30毫克的质子泵抑制剂奥美拉唑与每日1克西咪替丁相比，是否能加速溃疡愈合和缓解疼痛。在入组后的两周、四周和六周，接受奥美拉唑治疗的患者溃疡愈合的比例（分别为54%、81%和86%）高于接受西咪替丁治疗的患者（分别为39%、73%和78%）（“意向性治疗”队列；两周时p<0.05）。在治疗的第一周，服用奥美拉唑的患者中疼痛缓解的比例更高（p<0.05）。未观察到严重的临床或生化副作用。奥美拉唑是治疗幽门管胃溃疡患者的有效药物。
